earnings
confidence high
sentiment positive
materiality 0.85
Delcath prelim FY2025 revenue $85.2M, HEPZATO $78.8M, cash $91M
DELCATH SYSTEMS, INC.
2025-FY EPS
reported $0.07
vs consensus -$0.06
▲ beat
(+211.3%)
- Total Q4 revenue ~$20.7M, FY revenue ~$85.2M; HEPZATO KIT Q4 ~$19.0M, FY ~$78.8M.
- CHEMOSAT Q4 revenue ~$1.7M, FY ~$6.4M.
- Cash and short-term investments ~$91.0M as of Dec 31, 2025; no debt.
- 628,572 shares repurchased for $6.0M under $25M buyback program.
- 25 active sites; ~140% growth in HEPZATO procedure volume YoY; positive operating cash flow in Q4.